Across TCGA pan-cancer cohorts, TRAV19 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TRAV19 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher TRAV19 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRAV19 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, SKCM, and BLCA are the cancer types where TRAV19 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.282	0.692	.014	18	view →
SKCM	OS	Median	IV	0.415	0.861	.014	9	view →
BLCA	OS	Median	All	0.188	0.687	.020	6	view →
UCEC	DFS	Median	II,III,IV	1.000	0.310	.029	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: TRAV19 tumor-vs-normal RNA expression · all TRAV19 data types